TerminatedPhase 3NCT03150420

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

Studying Calciphylaxis

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hope Pharmaceuticals
Principal Investigator: Craig Sherman, MD
Hope Pharmaceuticals
Intervention: Sodium Thiosulfate(drug)
Enrollment: 29 enrolled
Eligibility: 18 years · All sexes
Timeline: 2017 – 2020

Study locations (21)

Mayo Clinic, Jacksonville, Florida, United States
Northwestern University Hospital, Chicago, Illinois, United States
Loyola University Medical Center, Maywood, Illinois, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Veterans Administration Medical Center, Albany, New York, United States
The Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States
Sanford Health, Fargo, North Dakota, United States
Cleveland Clinic, Cleveland, Ohio, United States
Rhode Island Hospital, Providence, Rhode Island, United States
University of Virginia Health System, Charlottesville, Virginia, United States
Veterans Administration Medical Center, Salem, Virginia, United States
University of Calgary Foothills Medical Center, Calgary, Alberta, Canada
University of Alberta Hospital, Edmonton, Alberta, Canada
Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
+6 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03150420 on ClinicalTrials.gov

Other trials for Calciphylaxis

Additional recruiting or active studies for the same condition.

See all trials for Calciphylaxis →

← Back to all trials